NDC 68001-372-33 - Cyclophosphamide
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68001-372
- Requested NDC
- 68001-372-33
- Package NDCs from labels
- 68001-372-33, 68001-372-32
- Manufacturer
- BluePoint Laboratories | Amneal Oncology Private Limited
- Effective date
- 2021-07-07
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cyclophosphamide - BluePoint Laboratories | Amneal Oncology Private Limited | BluePoint Laboratories | Amneal Oncology Private Limited | 2021-07-07 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 68001-372-32 | EA - Each | 68001-372 | c89d7173-ed4f-4b20-b5bc-3933067dc12f | 1 | 2018-12-13 |
| 68001-372-33 | EA - Each | 68001-372 | 0b86eb94-965a-4637-83e3-51fee2aef3cc | 1 | 2018-12-13 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Alembic Pharmaceuticals Inc. | 3d6e68b1-5120-4cbb-a9d2-fb09d1b74ea1 | 2024-12-10 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | NorthStar Rx LLC | 76f057be-e3da-0a89-e053-2a91aa0a8438 | 2024-11-20 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Hikma Pharmaceuticals USA Inc. | 8135b917-882f-4b4c-99b7-fa8ea54af4bf | 2024-11-19 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Fresenius Kabi USA, LLC | 31986d36-a1bf-4903-93a4-ce7386241ba1 | 2024-10-09 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Avyxa Pharma, LLC | 6f593585-e0dd-48bc-bd2b-c6c787e0b98c | 2024-07-26 | Warnings, Adverse reactions | 8N3DW7272P |
| Cyclophosphamide | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | Baxter Healthcare Company | 34dbffee-80e0-49c3-90e8-95713a0b7fbe | 2024-04-10 | Warnings, Adverse reactions | 8N3DW7272P |
| c688325c-7953-590a-e053-2995a90a50e0 | 457ede7d-d2f9-49a3-9de7-651f64a210e1 | 2021-07-07 | Warnings, Adverse reactions | c688325c-7953-590a-e053-2995a90a50e0 457ede7d-d2f9-49a3-9de7-651f64a210e1 | ||
| Cyclophosphamide | CYCLOPHOSPHAMIDE | Baxter Healthcare Corporation | 769ded74-6186-40a8-8e44-ceff67287451 | 2020-08-07 | Warnings, Adverse reactions | 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | cef038cc-efab-46d9-99c2-95bb11d6c9bc | 2017-03-15 | Warnings, Adverse reactions | 8N3DW7272P |
| CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | Baxter Healthcare Company | 6bae5c14-9e87-4fb6-ae9c-4d875c1ecffe | 2017-03-15 | Warnings, Adverse reactions | 8N3DW7272P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.